FR22C1062I1 - Thérapie de remplacement enzymatique d'escalade de doses pour le traitement du déficit en sphingomyélinase acide - Google Patents

Thérapie de remplacement enzymatique d'escalade de doses pour le traitement du déficit en sphingomyélinase acide

Info

Publication number
FR22C1062I1
FR22C1062I1 FR22C1062C FR22C1062C FR22C1062I1 FR 22C1062 I1 FR22C1062 I1 FR 22C1062I1 FR 22C1062 C FR22C1062 C FR 22C1062C FR 22C1062 C FR22C1062 C FR 22C1062C FR 22C1062 I1 FR22C1062 I1 FR 22C1062I1
Authority
FR
France
Prior art keywords
enzy
treatment
replacement therapy
dose escalation
acid sphingomyelinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1062C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Icahn School of Medicine at Mount Sinai
Original Assignee
Genzyme Corp
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1062(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Icahn School of Medicine at Mount Sinai filed Critical Genzyme Corp
Publication of FR22C1062I1 publication Critical patent/FR22C1062I1/fr
Application granted granted Critical
Publication of FR22C1062I2 publication Critical patent/FR22C1062I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)
FR22C1062C 2009-08-28 2022-12-15 Thérapie de remplacement enzymatique d'escalade de doses pour le traitement du déficit en sphingomyélinase acide Active FR22C1062I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
EP10812683.0A EP2470199B1 (fr) 2009-08-28 2010-08-28 Thérapie de substitution enzymatique à doses croissantes permettant de traiter un déficit en sphingomyélinase acide
PCT/US2010/047057 WO2011025996A2 (fr) 2009-08-28 2010-08-28 Thérapie de substitution enzymatique à doses croissantes permettant de traiter un déficit en sphingomyélinase acide

Publications (2)

Publication Number Publication Date
FR22C1062I1 true FR22C1062I1 (fr) 2023-02-03
FR22C1062I2 FR22C1062I2 (fr) 2023-12-29

Family

ID=43625265

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1062C Active FR22C1062I2 (fr) 2009-08-28 2022-12-15 Thérapie de remplacement enzymatique d'escalade de doses pour le traitement du déficit en sphingomyélinase acide

Country Status (26)

Country Link
US (9) US8349319B2 (fr)
EP (3) EP3482767B1 (fr)
JP (7) JP5955219B2 (fr)
KR (5) KR20200034828A (fr)
CN (3) CN105999238A (fr)
AU (5) AU2010286550B2 (fr)
BR (1) BR112012004377A2 (fr)
CA (1) CA2773133A1 (fr)
CL (1) CL2012000495A1 (fr)
CY (1) CY1122128T1 (fr)
DK (2) DK3482767T3 (fr)
ES (2) ES2902229T3 (fr)
FR (1) FR22C1062I2 (fr)
HR (2) HRP20211992T1 (fr)
HU (3) HUE046598T2 (fr)
IL (3) IL300625A (fr)
LT (2) LT2470199T (fr)
MX (1) MX356873B (fr)
NL (1) NL301211I2 (fr)
PL (2) PL3482767T3 (fr)
PT (2) PT3482767T (fr)
RU (3) RU2731616C2 (fr)
SI (2) SI2470199T1 (fr)
TR (1) TR201911293T4 (fr)
WO (1) WO2011025996A2 (fr)
ZA (2) ZA201201435B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
ES2905616T3 (es) 2007-06-06 2022-04-11 Genzyme Corp Terapia génica para enfermedades de almacenamiento lisosómico
PT3482767T (pt) * 2009-08-28 2021-12-29 Icahn School Med Mount Sinai Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida
US8882701B2 (en) * 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
WO2011146143A2 (fr) 2010-05-21 2011-11-24 Ohmx Corporation Détection du cancer par dosage de l'activité enzymatique du psa
CN107080747B (zh) 2011-03-18 2021-02-26 建新公司 葡萄糖基神经酰胺合酶抑制剂
DK2753346T3 (da) 2011-09-07 2020-05-25 Sinai School Medicine Ceramidase og celledifferentiering
MX359328B (es) * 2011-11-15 2018-09-25 Centogene Ag Metodo para el diagnostico de enfermedad de niemann-pick.
EP3679923B1 (fr) 2012-06-01 2021-08-04 Icahn School of Medicine at Mount Sinai Niveaux de céramide dans le traitement et la prévention d'infections
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
JP6832158B2 (ja) * 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
ES2731920T3 (es) * 2013-05-14 2019-11-19 Centogene Ag Método para el diagnóstico de la enfermedad de Niemann-Pick
HUE047863T2 (hu) * 2013-06-07 2020-05-28 Genzyme Corp Marker savas szfingomielináz rendellenességekhez és alkalmazásai
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
EP3672622B1 (fr) * 2017-08-24 2023-11-08 Genzyme Corporation Sphingomyelinase acide humain recombinante pour l'utilisation dans le traitement d'états osseux anormaux chez des patients présentant une déficience en sphingomyélinase acide
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
UY38238A (es) 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
US11857512B2 (en) 2020-07-24 2024-01-02 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) * 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
CN100410268C (zh) 1998-12-23 2008-08-13 博伊斯汤普生植物研究所 免疫原性的乙型肝炎表面抗原在转基因植物中的表达
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
WO2001097829A2 (fr) * 2000-06-19 2001-12-27 Genzyme Corporation Traitement de substitution enzymatique, therapie genique et therapie par petites molecules pour maladies liees au stockage lysosomal
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
EP1974752B1 (fr) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Cible infracellulaire de protéines thérapeutiques
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
AU2003224880A1 (en) * 2002-04-05 2003-10-27 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
CA2528427A1 (fr) 2003-06-12 2004-12-23 Genzyme Corporation Sphingomyelinase acide humaine modifiee a activite accrue, et ses procedes de production
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CN101214249A (zh) 2003-11-25 2008-07-09 纽约大学西奈山医学院 尼曼-皮克病的基于陪伴分子的治疗
ATE468390T1 (de) 2004-10-13 2010-06-15 Protalix Ltd System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
KR20080082984A (ko) 2005-12-15 2008-09-12 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 혈장 및 조직의 스핑고마이엘린 및 포스파티딜콜린의효소적 측정 방법
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
WO2007091250A2 (fr) 2006-02-06 2007-08-16 The Medical Research And Infrastructure Fund Of The Tel-Aviv Sourasky Medical Center Enzymotherapie de remplacement pour le traitement des maladies lysosomiales
CA2641359C (fr) 2006-02-09 2022-10-04 Genzyme Corporation Administration intraventriculaire lente
CA2642054C (fr) 2006-02-13 2017-11-21 Fraunhofer Usa, Inc. Antigenes de la grippe, compositions de vaccins et procedes associes
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
JP5658167B2 (ja) 2008-12-16 2015-01-21 ジェンザイム・コーポレーション オリゴ糖−タンパク複合体
PT3482767T (pt) * 2009-08-28 2021-12-29 Icahn School Med Mount Sinai Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida
JP6175431B2 (ja) * 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法

Also Published As

Publication number Publication date
AU2018204156A1 (en) 2018-06-28
JP7395693B2 (ja) 2023-12-11
US20190151419A1 (en) 2019-05-23
RU2015145255A3 (fr) 2019-08-12
MX2012002449A (es) 2012-03-14
US8658162B2 (en) 2014-02-25
US8349319B2 (en) 2013-01-08
PL2470199T3 (pl) 2019-11-29
JP2016153408A (ja) 2016-08-25
KR20210107153A (ko) 2021-08-31
JP2023012499A (ja) 2023-01-25
ZA201601362B (en) 2017-05-31
US9114139B2 (en) 2015-08-25
KR20220104271A (ko) 2022-07-26
US20210077593A1 (en) 2021-03-18
JP2024026214A (ja) 2024-02-28
ES2738859T3 (es) 2020-01-27
EP2470199A4 (fr) 2013-03-27
EP3482767B1 (fr) 2021-10-06
JP2020090513A (ja) 2020-06-11
CN102596232A (zh) 2012-07-18
BR112012004377A2 (pt) 2017-12-12
JP2013502933A (ja) 2013-01-31
US10188705B2 (en) 2019-01-29
CY1122128T1 (el) 2020-11-25
EP2470199A2 (fr) 2012-07-04
JP6952810B2 (ja) 2021-10-20
FR22C1062I2 (fr) 2023-12-29
PT3482767T (pt) 2021-12-29
AU2010286550A1 (en) 2012-03-15
NL301211I2 (nl) 2023-02-02
JP6251307B2 (ja) 2017-12-20
PL3482767T3 (pl) 2022-02-14
US20160120957A1 (en) 2016-05-05
SI2470199T1 (sl) 2019-11-29
US8709408B2 (en) 2014-04-29
CL2012000495A1 (es) 2014-02-07
US9655954B2 (en) 2017-05-23
AU2010286550B2 (en) 2016-05-19
EP3482767A1 (fr) 2019-05-15
SI3482767T1 (sl) 2022-03-31
IL266915A (en) 2019-07-31
DK3482767T3 (da) 2021-12-20
WO2011025996A2 (fr) 2011-03-03
US20130078230A1 (en) 2013-03-28
EP3998078A1 (fr) 2022-05-18
JP2018076322A (ja) 2018-05-17
JP5955219B2 (ja) 2016-07-20
ES2902229T3 (es) 2022-03-25
IL266915B2 (en) 2023-07-01
AU2016216625A1 (en) 2016-09-15
US20130078231A1 (en) 2013-03-28
PT2470199T (pt) 2019-08-07
MX356873B (es) 2018-06-18
KR102608546B1 (ko) 2023-12-04
US20180055916A1 (en) 2018-03-01
HRP20211992T1 (hr) 2022-04-01
IL218324B (en) 2019-05-30
US20220305091A1 (en) 2022-09-29
KR20120081077A (ko) 2012-07-18
WO2011025996A3 (fr) 2012-03-15
LT3482767T (lt) 2022-01-10
US20110052559A1 (en) 2011-03-03
IL218324A0 (en) 2012-04-30
AU2024201085A1 (en) 2024-03-07
KR102608551B1 (ko) 2023-12-04
KR102094253B1 (ko) 2020-03-31
HUE046598T2 (hu) 2020-03-30
LT2470199T (lt) 2019-10-10
HUE057440T2 (hu) 2022-05-28
HRP20191385T1 (hr) 2019-11-01
AU2020256322A1 (en) 2020-11-12
AU2020256322B2 (en) 2024-02-29
US20140335070A1 (en) 2014-11-13
RU2020128994A (ru) 2022-03-02
EP2470199B1 (fr) 2019-05-22
RU2015145255A (ru) 2019-01-11
CA2773133A1 (fr) 2011-03-03
RU2731616C2 (ru) 2020-09-07
WO2011025996A9 (fr) 2011-08-25
DK2470199T3 (da) 2019-08-05
ZA201201435B (en) 2020-05-27
NL301211I1 (nl) 2022-12-28
AU2016216625B2 (en) 2018-07-05
TR201911293T4 (tr) 2019-08-21
CN105999238A (zh) 2016-10-12
CN106047835A (zh) 2016-10-26
AU2018204156B2 (en) 2020-07-16
KR20230164773A (ko) 2023-12-04
JP2022003065A (ja) 2022-01-11
RU2569744C2 (ru) 2015-11-27
KR20200034828A (ko) 2020-03-31
IL300625A (en) 2023-04-01
HUS2200050I1 (hu) 2022-12-28
IL266915B1 (en) 2023-03-01
JP7167281B2 (ja) 2022-11-08
RU2012111823A (ru) 2013-10-10

Similar Documents

Publication Publication Date Title
FR22C1062I1 (fr) Thérapie de remplacement enzymatique d'escalade de doses pour le traitement du déficit en sphingomyélinase acide
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
MX2020004099A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
ZA201208535B (en) Formulations of quinones for the treatment of ophthalmic diseases
IL225668A0 (en) The compositions for the treatment of disorders in the upper respiratory tract
EP2776059A4 (fr) Compositions pharmaceutiques contenant des protéases et procédés pour le traitement de maladies liées au stockage lysosomal
FR20C1026I1 (fr) Ciclesonide pour le traitement de maladies des voies respiratoires chez les chevaux
IL260078B (en) Therapy used to treat Gaucher disease
HK1182015A1 (zh) 活性藥物化合物用於治療中樞神經系統病症的用途
EP2306824A4 (fr) Administration par ionophorèse de curcumine et analogues de curcumine destinés au traitement de la maladie d'alzheimer
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
IL232384A (en) Use of lupanate compounds or lupanic acid for the preparation of anti-gout drugs
EP2398789A4 (fr) Inhibiteurs de bêta-sécrétase de type spiropyrrolidine pour le traitement de la maladie d'alzheimer
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
SMT201600479B (it) Nuove soluzioni terapeutiche per il trattamento di condizioni neuroinfiammatorie
BR112013020195A2 (pt) composições farmacêuticas livres de citrato compreendendo anakinra
FR2953723B1 (fr) Composition pharmaceutique destinee au traitement des pathologies orthopediques
FR2981060B1 (fr) Procede de valorisation des effluents d'acide chlorofluorhydrique
IT1404270B1 (it) Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid
PT2344166E (pt) Composição farmacêutica para o tratamento da irritação gastrointestinal
FR2976807B1 (fr) Composition pharmaceutique pour le traitement de la dependance chez l'etre humain
FR2953412B1 (fr) Medicament pour le traitement des ulceres gastro-intestinaux
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
IT1397219B1 (it) Composizione farmaceutica o dietetica per il trattamento dell'atopia
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders